research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-04. Anything still debated is marked as such rather than presented as settled.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Gallrein served in the U.S. military for three decades, from 1984 to 2014, serving with U.S. Navy SEAL Team Six. He rose to the rank of Navy captain, as he was deployed to Panama, Afghanistan, Iraq, and the Persian Gulf. He was inspired to join the military by President Ronald Reagan. By November 1985, Gallrein had become an ensign in the United States Navy and was stationed at Little Creek Naval Amphibious Base. During his 2026 political campaign, Gallrein said that he had received four Bronze Star Medals; Gallrein was awarded three—the fourth appears to be the bronze star on his Combat Parachutist Badge. He also has two Presidential Unit Citations. After his military career, Gallrein turned to becoming a dairy farmer and a business owner operating Circle G Farm and Stables in Shelby County since 2014.
=== CITES and species risk === According to the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), products made from endangered species can be legally traded after certification. CITES lists the Nile crocodile under Appendix II which means a species that is not necessarily currently endangered, but which is in danger of becoming extinct unless trade in specimens is strictly regulated to prevent uses that threaten its survival. The collection, processing, domestic trading, and exporting of all crocodile products must be controlled. Over catching of this animal has led to the decline of this species in wild populations. Efforts are made to preserve the existing habitat of this species. Crocodiles have been bred in farms since the early twentieth century, where Thai crocodile farming industry is currently the largest in the world. Breeding this animal under captivity is a developing industry in some parts of the world.
The whole structure of the membrane-bound vascular enzyme is composed of five parts: two cytosolic subunits (p47phox and p67phox), a cytochrome b558 which consists of gp91phox, p22phox and a small G protein Rac. Generation of the superoxide in vascular NADPH occurs by a one-electron reduction of oxygen via the gp91phox subunit, using reduced NADPH as the electron donor. The small G protein carries an essential role in the activation of the oxidase by switching between a GDP-bound (inactive) and GTP-linked (active) forms.
Sources: en.wikipedia.org
== History == Fyn is a member of the Src-family of kinases (SFK), the first proto-oncogene to be identified. The discovery of the Src-family in 1976 led to the Nobel prize for medicine in 1989 for J.M Bishop and E.M. Varmus. Fyn was first identified in 1986 as Syn or Slk through probes derived from v-yes and v-fgr. A common feature of SFKs is that they are commonly upregulated in cancers. Fyn is functionally distinct from its family members in that it interacts with FAK and paxillin (PXN) in the regulation of cell morphology and motility.
When the mixed sulfates were pure enough, they were once more converted to mixed chlorides; barium and radium thereafter were separated by fractional crystallisation while monitoring the progress using a spectroscope (radium gives characteristic red lines in contrast to the green barium lines), and the electroscope. After the isolation of radium by Marie and Pierre Curie from uranium ore from Jáchymov, several scientists started to isolate radium in small quantities. Later, small companies purchased mine tailings from Jáchymov mines and started isolating radium. In 1904, the Austrian government nationalised the mines and stopped exporting raw ore. Until 1912, when radium production increased, radium availability was low. The formation of an Austrian monopoly and the strong urge of other countries to have access to radium led to a worldwide search for uranium ores. The United States took over as leading producer in the early 1910s, producing 70 g total from 1913 to 1920 in Pittsburgh alone. The Curies' process was still used for industrial radium extraction in 1940, but mixed bromides were then used for the fractionation. If the barium content of the uranium ore is not high enough, additional barium can be added to carry the radium. These processes were applied to high grade uranium ores but may not have worked well with low grade ores. Small amounts of radium were still extracted from uranium ore by this method of mixed precipitation and ion exchange as late as the 1990s, but as of 2011, it is extracted only from spent nuclear fuel.
== Function == This gene is a member of the transferrin receptor-like family and encodes a single-pass type II membrane protein with a protease associated (PA) domain, an M28 peptidase domain and a transferrin receptor-like dimerization domain. This protein mediates cellular uptake of transferrin-bound iron and mutations in this gene have been associated with hereditary hemochromatosis type III. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized.
== Treatment == For people with the FOLR1 mutation, even when the systemic deficiency is corrected by folate (the oxidized form - folic acid), the cerebral deficiency remains, and must be treated with folinic acid. Folinic acid is a metabolically active form of folate that can be easily introduced into the folate cycle. A typical dose that is administered to children is 0.5–1 mg/kg daily, but the dose can be increased depending on the severity of symptoms and the age of the child. Over time, the treatment with folinic acid has shown to reduce a variety of symptoms of CFD. The treatment of folinic acid can lead to improvements in walking, speech, interpersonal skills and reduction in seizures. Success depends on early initiation of treatment. Starting the folinic acid treatment before the age of six is more advantageous for the child with CFD. If the treatment is started after the age of six, its results are not as effective. Treatment requires taking folinic acid for lengthy periods. Fewer than 20 people with the FOLR1 defect have been described in the medical literature. Folinic acid (5-formyl-THF, 5-fTHF) also appears useful for some other forms of CFD. Pharmacologic doses of folinic acid has also led to reversal of some symptoms in children diagnosed with cerebral folate deficiency and testing positive for autoantibodies to folate receptor alpha. It also appears useful in DHFR deficiency and AADC deficiency. 5-MTHF (5-methyl-THF) is also available as a drug (levomefolic acid). It is "thought to be the most efficient way to restore CSF 5-MTHF concentrations".
Sources: en.wikipedia.org
=== Other live performances === Clipse performed at the DuSable Black History Museum in Chicago, Illinois on August 24, 2024, for the Pepsi Dig In Day Block Party—a free event celebrating Black-owned restaurants. Clipse performed "Ace Trumpets" on June 26, 2025, for A Colors Show—a live performance series by German media company ColorsxStudios. Audio of the performance was released as a single on streaming services the same day. They performed an NPR Tiny Desk concert on July 11, concurrently with the album's release. A few days later, on July 15, they performed "The Birds Don't Sing" on The Tonight Show Starring Jimmy Fallon. During 2025 Jubilee, the "World Meeting on Human Fraternity 2025" took place on the St. Peter's Square at the Vatican City on 12 and 13 September, with concert of Andrea Bocelli, Pharrell Williams with the gospel choir Voices of Fire, and John Legend. Clipse performed the song "The Birds Don't Sing" along with John Legend at the second date during the Grace For The World concert on September 13, making history for being the first rappers to ever perform at the Vatican City. The duo performed "So Be It" on Jimmy Kimmel Live! in October 2025.
=== Part One === The first part of the film was created by Toronto-based David and Ian Purchase, the two of whom are collectively referred to as the Purchase Brothers. Before Escape from City 17, the Purchase Brothers had directed several commercials, including one for Coca-Cola. David contended that they worked as commercial directors in order to support their independent projects. Both being fans of the Half-Life series, the two decided to start Escape from City 17 as a way "to showcase and promote their talents further, and experiment with several post-production techniques they had developed." The two had a budget of Can$500; the computer equipment and software employed for the development of the film belonged to the Purchase Brothers from previous projects. According to David, the money was spent on the live-action elements of the film, saying that "the costumes, and used/broken airsoft guns made up the bulk of the budget." The two had no crew to support them, and were not paid for their work. Many of the elements of the film, such as the background, the Citadel, and the gunships, were extracted from Half-Life 2. The elements were then "graphically enhanced, and incorporated into the live action with a lot of complicated tracking and rotoscoping." The background used for the film's opening scene is the panorama of Riga. The "main set" of Part One was filmed at a trainyard with "active security." This made filming the short difficult, as the Purchase Brothers "tend not to get permits" to use the trainyard for the film.
=== Production of glycol ethers === The major industrial esters of mono-, di-, and triethylene glycols are methyl, ethyl, and normal butyl ethers, as well as their acetates and phthalates. The synthesis involves reaction of the appropriate alcohol with ethylene oxide:
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.